Recent advances in personalized colorectal cancer research

Sarah Kraus, Ilana Nabiochtchikov, Shiran Shapira, Nadir Arber*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations

Abstract

Colorectal cancer is one of the most prevalent cancers and a leading cause of. cancer-related death. It is also curable if detected early. The prognosis for metastatic colorectal cancer remains poor and resistance to chemotherapy is still a major obstacle in effective treatment. While many patients do not clinically benefit from chemotherapy, others experience adverse reactions resulting in dose modifications or treatment withdrawal, thereby reducing treatment efficacy. Research. efforts attempt to identify reliable biomarkers which will guide clinicians in decision making, while matching suitable therapeutic regimens. We here review currently known molecular biomarkers used for the personalized treatment of colorectal cancer.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalCancer Letters
Volume347
Issue number1
DOIs
StatePublished - 28 May 2014

Keywords

  • Biomarkers
  • Colorectal cancer (CRC)
  • Epigenetic markers
  • KRAS
  • Monoclonal antibodies (mAbs)
  • Oncotype

Fingerprint

Dive into the research topics of 'Recent advances in personalized colorectal cancer research'. Together they form a unique fingerprint.

Cite this